A Study of CD4+Foxp3+Treg and CD8+Foxp3+Treg Cells in Patients with Rheumatoid Arthritis

Document Type : Original Article(s)

Authors

1 Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Radiotherapy and Oncology, Seyed-Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

5 Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

6 Assistant Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Rheumatoid arthritis (RA) is defines as a Th1 dominant disease. Tregs cell are a rather new group of T cells that regulates other immune cells including Th1 and Th2. Foxp3 is a lineage-determining factor for Treg cells. Several subsets of Foxp3+regulatory T cells are ever identified. In this study we investigated the frequency of CD4+Foxp3+Treg and CD8+Foxp3+Treg cells in patients with rheumatoid arthritis.Methods: Peripheral blood samples were obtained from 31 patients with rheumatoid arthritis and 21 healthy controls. Monoclonal antibodies including anti-CD4 and anti-CD8 and anti-Foxp3 were used and the staining process was performed. Flow cytometry were applied to evaluate the markers.Findings: The percentage of CD4+Foxp3+Treg cells was 1.03% ± 0.28 % in rheumatoid arthritis and 1.25% ± 0.3% in control group (P = 0.010). The percentage of CD8+Foxp3+ Treg cells was 0.79 ± 0.18, and 0.63 ± 0.16 in rheumatoid arthritis and control groups respectively (P = 0.002). The WBC and Lymphocytes population in rheumatoid arthritis group were higher than control group (P = 0.001). Conclusion: These data demonstrate that frequency of Treg cells might be involved in the pathogenesis of rheumatoid arthritis. This may be a contributory factor in the susceptibility to rheumatoid arthritis (Th1 dominant), or it may achieved during the progression of the disease.

Keywords

References

  1. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169(5): 2756-61.
  2. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8(9): 950-7.
  3. Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther 2008; 10(Suppl 1): S1.
  4. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8(3): 223-46.
  5. McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002; 23(9): 450-5.
  6. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2(6): 389-400.
  7. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133(5): 775-87.
  8. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50(9): 2775-85.
  9. Mottonen M, Heikkinen J, Mustonen L, Isomaki P, Luukkainen R, Lassila O. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140(2): 360-7.
  10. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001; 2(4): 301-6.
  11. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8(3): 277-84.
  12. Pillai V, Karandikar NJ. Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation? Immunol Lett 2007; 114(1): 9-15.
  13. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299(5609): 1057-61.
  14. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445(7129): 766-70.
  15. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27(1): 20-1.
  16. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009; 76(1): 10-4.
  17. Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, et al. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat 2006; 98(1): 17-29.
  18. Lawson CA, Brown AK, Bejarano V, Douglas SH, Burgoyne CH, Greenstein AS, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006; 45(10): 1210-7.
  19. Cao D, van VR, Klareskog L, Trollmo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004; 6(4): R335-R346.
  20. Han GM, O'Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol 2008; 253(1-2): 92-101.
  21. Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973; 16(0): 265-336.
  22. Rech AJ, Mick R, Kaplan DE, Chang KM, Domchek SM, Vonderheide RH. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010; 59(4): 599-607.
  23. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008; 173(5): 1389-96.
  24. Falgarone G, Duclos M, Boissier MC. TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice. Joint Bone Spine 2007; 74(6): 523-6.
  25. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009; 30(5): 656-65.
  26. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 2010; 67(5): 625-38.
  27. Frisullo G, Nociti V, Iorio R, Plantone D, Patanella AK, Tonali PA, et al. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Hum Immunol 2010; 71(5): 437-41.
  28. Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, James I, et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007; 21(12): 1525-34.
Journal of Isfahan Medical School
Volume 29, Issue 155 - Serial Number 155
September and October 2011
Pages 1412-1419

Files

History

  • Receive Date: 28 August 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics